This study was designed to establish the prevalence of
HLA-B*5701 at HIV-1 infected individuals in Brazil. A total of 517 consecutive
individuals were followed in this study from February 2009 through July 2011. The presence of HLA-B*5701 was
determined by Nested-PCR with HLA-B*57 and HLA-B*5701 sequence-specific primers (PCR-SSP). The expression of
HLA-B*57 was negative in the 385 (74.5%) and positive in the
103 (19.9%) of infected
individuals. Among these, the expression of HLA-B5701
was positive in the 29 (5.6%) of individuals. No demographic or ethnic
differences were found between HLA-B*57/HLA-B*5701
HIV-1 negative patients, with a prevalence of Caucasians (57.1%) individuals.
During the period
of study, 68 patients were submited to an abacavir contain- ing regimen. The HLA-B*5701
allele was observed in 7 (10.3%)
patients, with a significant incidence of Hypersensitivity reactions at 4 of them (p < 0.001). Conclusions:
Although Brazilian population consists of a
mixture of individuals of Caucasian, African and Native American genetic
background, prevalence of HLA-B*5701 in this population is similar to the one
found in pure Caucasians.
Mallal, S., Phillips, E., Carosi, G., Molina, J.M., Workman, C., Tomazic, J., et al. (2008) HLA B*5701 Screening for Hypersensitivity to Abacavir. The New England Journal of Medicine, 358, 568-579. http://dx.doi.org/10.1056/NEJMoa0706135
Young, B., Squires, K., Patel, P., Dejesus, E., Bellos, N., Berger, D., et al. (2008) First Large, Multicenter, Open-Label Study Utilizing HLA-B*5701 Screening for Abacavir Hypersensitivity in North America. AIDS, 20, 1673-1675. http://dx.doi.org/10.1097/QAD.0b013e32830719aa
Martin, A., Nolan, D., Gaudieri, S., Almeida, C.A., Nolan, R., James, I., et al. (2004) Predisposition to Abacavir Hypersensitivity Conferred by HLA-B*5701 and a Haplotypic Hsp70-Hom Variant. Proceedings of the National Academy of Sciences of the United States of America, 101, 4180-4185. http://dx.doi.org/10.1073/pnas.0307067101
Martin, A.M., Nolan, D. and Mallal, S. (2005) HLA-B*5701 Typing by Sequence-Specific Amplification: Validation and Comparison with Sequence-Based Typing. Tissue Antigens, 65, 571-574. http://dx.doi.org/10.1111/j.1399-0039.2005.00401.x
Lucas, A., Nolan, D. and Mallal, S. (2007) HLA-B*5701 Screening for Susceptibility to Abacavir Hypersensitivity. Journal of Antimicrobial Chemotherapy, 59, 591-593. http://dx.doi.org/10.1093/jac/dkl557
Mallal, S., Nolan, D., Witt, C., Masel, G., Martin, A.M., Moore, C., et al. (2002) Association between Presence of HLA-B*5701, HLA-DR7 and HLA-DQ3 and Hypersensitivity to HIV-1 Reverse-Transcriptase Inhibitor Abacavir. Lancet, 359, 727-732. http://dx.doi.org/10.1016/S0140-6736(02)07873-X
Phillips, E., Rauch, A., Nolan, D., Martin, A., Almeida, C., Knowles, S., et al. (2007) Genetic Characterization of Patients with MHC Class I Mediated Abacavir Hypersensitivity Reaction. 4th IAS Conference on HIV Pathogenesis, Treatment and Prevention, Sydney, 22-25 July 2007, Abstract No. MOPEB001.
Parczewski, M., Leszczyszyn-Pynka, M., Wnuk, A., Urbañska, A., Fuksiñska, K., Bander, D., et al. (2010) Introduction of Pharmacogenetic Screening for the Human Leucocyte Antigen (HLA) B*5701 Variant in Polish HIV-Infected Patients. HIV Medicine, 11, 345-348. http://dx.doi.org/10.1111/j.1468-1293.2009.00787.x
Waters, L.J., Mandalia, S., Gazzard, B. and Nelson, M. (2007) Prospective HLA-B*5701 Screening and Abacavir Hypersensitivity: A Single Centre Experience. AIDS, 21, 2533-2549. http://dx.doi.org/10.1097/QAD.0b013e328273bc07
Rauch, A., Nolan, D., Martin, A., McKinnon, E., Almeida, C. and Mallal, S. (2006) Prospective Genetic Screening Decreases the Incidence of Abacavir Hypersensitivity Reactions in the Western Australian HIV Cohort Study. Clinical Infectious Diseases, 43, 99-102. http://dx.doi.org/10.1086/504874
Zucman, D., Truchis, P., Majerholc, C., Stegman, S. and Caillat-Zucman, S. (2007) Prospective Screening for Human Leukocyte Antigen-B*5701 Avoids Abacavir Hypersensitivity Reaction in the Ethnically Mixed French HIV Population. Journal of Acquired Immune Deficiency Syndromes, 45, 1-3. http://dx.doi.org/10.1097/QAI.0b013e318046ea31
Hammond, E., Mamotte, C., Nolan, D. and Mallal, S. (2007) HLA-B*5701 Typing: Evaluation of an Allele-Specific Polymerase Chain Reaction Melting Assay. Tissue Antigens, 70, 58-61. http://dx.doi.org/10.1111/j.1399-0039.2007.00840.x
Saag, M., Balu, R., Phillips, E., Brachman, P., Martorell, C., Burman, W., et al. (2008) High Sensitivity of Human Leukocyte Antigen-b*5701 as a Marker for Immunologically Confirmed Abacavir Hypersensitivity in White and Black Patients. Clinical Infectious Diseases, 46, 1111-1118. http://dx.doi.org/10.1086/529382
Sun, H.Y., Hung, C.C., Lin, P.H., Chang, S.F., Yang, C.Y., Chang, S.Y., et al. (2007) Incidence of Abacavir Hypersensitivity and Its Relationship with HLA-B*5701 in HIV-Infected Patients in Taiwan. Journal of Antimicrobial Chemotherapy, 60, 599-604.
Hughes, S., Parry-Billingsc, K., Givens, N., Wong, D., Loeschel, E., Parada, P., et al. (2006) Genetic Screening Test for Abacavir Hypersensitivity—PREDICT-1: Description of a Novel Randomised Prospective Study Design to Determine the Clinical Utility of Prognostic Screening for HLA-B*5701 in 8th International Congress Drug Therapy in HIV Infection. Glaugow, Scotland UK.
Orkin, C., Wang, J., Bergin, C., Molina, J.M., Lazzarin, A., Cavassini, M., et al. (2010) An Epidemiologic Study to Determine the Prevalence of the HLA-B*5701 Allele among HIV-Positive Patients in Europe. Pharmacogenetics and Genomics, 20, 307-314. http://dx.doi.org/10.1097/FPC.0b013e3283390666